Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Free Cash Flow (2016 - 2025)

Guided Therapeutics (GTHP) has disclosed Free Cash Flow for 15 consecutive years, with -$291000.0 as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 12.35% to -$291000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.1 million through Dec 2025, up 4.56% year-over-year, with the annual reading at -$1.1 million for FY2025, 4.38% up from the prior year.
  • Free Cash Flow hit -$291000.0 in Q4 2025 for Guided Therapeutics, down from -$277000.0 in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $155000.0 in Q4 2021 to a low of -$744000.0 in Q3 2021.
  • Historically, Free Cash Flow has averaged -$352450.0 across 5 years, with a median of -$334000.0 in 2023.
  • Biggest five-year swings in Free Cash Flow: soared 146.83% in 2021 and later tumbled 320.65% in 2022.
  • Year by year, Free Cash Flow stood at $155000.0 in 2021, then crashed by 320.65% to -$342000.0 in 2022, then increased by 1.75% to -$336000.0 in 2023, then increased by 1.19% to -$332000.0 in 2024, then rose by 12.35% to -$291000.0 in 2025.
  • Business Quant data shows Free Cash Flow for GTHP at -$291000.0 in Q4 2025, -$277000.0 in Q3 2025, and -$169000.0 in Q2 2025.